Evidence map›Paper›PMID 32202085›Full record

ReviewThe world journal of men's health2021

Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review.

Young Jin Tak, Sang Yeoup Lee

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The world journal of men's health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05711758 (Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure), which is not on this map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05711758 recruitingnot on this mapstarted 2023, after this paper: background citation

Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure: A Pilot Study

TypeobservationalSponsorChristopher C. Thompson, MD, MScRan2023 to 2027Enrolled30ConditionsObesity, Obesity, Morbid, Obesity, Primary, Metabolic DiseaseArmsPSAM Treatment Patients
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 170 citations in OpenAlex.

  1. Effect of Citrus bergamia Supplementation on Body Composition in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Fat Browning Effects of Catalpol and Rhoifolin fromPharmaceuticals (Basel, Switzerland) · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. The beneficial Effects ofCurrent diabetes reviews · 2026
    Article
  14. Review
  15. Article
  16. Article
  17. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  18. Pharmaceuticals (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Young Jin TakDepartment of Family Medicine, Pusan National University School of Medicine, Yangsan, Korea.ORCID https://orcid.org/0000-0002-4645-5866
Sang Yeoup LeeFamily Medicine Clinic and Research Institute of Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.ORCID https://orcid.org/0000-0002-3585-9910
Pusan National University Hospital · KRPusan National University Yangsan Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbidities. Recent advances in anti-obesity drugs have enabled the potential of achieving clinically significant weight loss. Increasing evidence has shown that behavior-based interventions with one of these medications can result in greater weight loss than that elicited by usual care conditions. Data from most recent meta-analyses showed that the overall placebo-subtracted weight reduction (%) with the use of anti-obesity drugs for at least 12 months ranges from 2.9% to 6.8%; phentermine/topiramate (-6.8%) liraglutide (-5.4%), naltrexone/bupropion (-4.0%), lorcaserin (-3.1%), and orlistat (-2.9%). However, they have a high cost and may cause adverse outcomes depending on the individual. Very recently, on February 13, 2020, the US Food and Drug Administration requested withdrawal of lorcaserin from the market because a safety clinical trial showed an increased occurrence of cancer. Therefore the decision to initiate drug therapy in obese individuals should be made after the benefits and risks are considered. Thereafter, treatment should be tailored to specific patient subpopulations depending on their chronic conditions, comorbidities, and preferences. Herein, we provide an overview of the latest developments in weight loss medications, which may serve as one of the strategies for long-term obesity control.

Indexed as

LiraglutideLorcaserinNaltrexone/bupropionObesityOrlistatPhentermine/topiramate

Identifiers

PMID32202085
PMCPMC7994651
OpenAlexW3011747422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.